Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.79 - $15.68
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.40M
Enterprise Value$4.65M
Total Cash (Recent Filing)$88.00K
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.76
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit20.42
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsExceptionally high gross margins (~90%+) indicate strong product-level economics and pricing power for the electrophysiology catheter. Durable unit margins support scalability: as procedure volumes grow, incremental revenue can flow to operating leverage if fixed costs are managed, aiding long-term profitability potential.
Improving Revenue TrendReported revenue growth and positive growth metrics show early commercial traction for the core catheter product. Sustained top-line expansion from a small base, if maintained, underpins the path to scale by spreading fixed R&D and SG&A across more procedures and improving operating leverage over several quarters.
Access To Structured FinancingRecent private placements and convertible preferred financings provide near-term liquidity and a financing framework that can fund operations, acquisitions, and restructuring. Ready access to structured capital reduces immediate solvency risk and gives management flexibility to execute longer-term strategic plans.
Bears Say
Large Cash BurnPersistent negative operating and free cash flow of -$8.3M in 2025 demonstrates structural cash burn relative to revenue. Ongoing outflows force repeated capital raises, increase liquidity risk, and limit ability to invest in sustained commercialization absent material revenue growth or cost restructuring.
Deep UnprofitabilityVery large net losses relative to tiny revenue indicate the business remains far from break-even. Structural operating cost burden must be materially reduced or revenue must scale quickly; otherwise the company will continue to show negative returns and pressure equity value and retention of talent.
Dilution & Strategic Pivot RiskHeavy reliance on convertible preferred issuances and using equity to buy non-core aviation assets shifts capital away from the core medical device franchise and increases dilution risk. The strategic pivot and complex capital structure can distract management and dilute returns over the medium term.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.79 and its highest was $15.68 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.40M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 96 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 2,692,473 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Technical Analysis
Ownership Overview
0.52%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---